- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Changing the Cancer Landscape
Since the rise of genetics and advanced molecular biology, cancer research is a field that has become almost as obsessed with understanding aberrant metabolism as it is with devising therapies.
You are standing on top of a large, grassy hill. As it slopes down, the ground is uneven, forming pockets and smaller hilltops. More grassy slopes roll out around you to meet the horizon on all sides — a landscape of peaks and valleys, large and small, wildly irregular.
You have with you a large bag of slightly deflated basketballs. Ignoring the ludicrous and perplexing circumstances that must have led to you standing on a hill with so many useless basketballs, you decide you might as well toss one or two down the hill, to see what happens — they don’t bounce, but they’ll roll. Soon you’ve emptied the bag, sending dozens rolling off in every direction. Most of them find their way to a few deep, obvious valleys, before coming to rest. But one of them seems to be stuck – it’s caught in a groove along the hill that you stand on, but the groove is so slight that you hadn’t noticed it before.
It may seem alarming, but that basketball may be the reason we haven’t cured cancer yet.
Read the full story here: http://bit.ly/1bzTULI
Source: Scientific American
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
